Mental Health DailyResearch. Evidence. Perspective.Published research on aripiprazole.
Adults with bipolar I disorder who switched to an aripiprazole injection given every 2 months had more days covered by medication over the next 6 months than in the 6 months before, accordin…
Read articleA 2026 FAERS pharmacovigilance study of 28,938 dystonia reports found the strongest reporting signal for metoclopramide, while antipsychotics dominated the high-volume psychiatric medication…
Read articleA 2026 Neurological Sciences brief communication added 2 Tourette syndrome cases of aripiprazole-related oculogyric crisis — sustained, involuntary upward eye deviation from extraocular-musc…
Read articleSocial media has emerged as a pivotal source of real-world evidence, especially in understanding patient experiences and perceptions regarding the treatment of severe mental disorders such a…
Read articleAntidepressant-resistant major depressive disorder (AR-MDD) poses significant challenges in psychiatric treatment. Antipsychotics like aripiprazole (ARI) and brexpiprazole (BRE) have emerged…
Read articleIt is estimated that 40% of U.S. adults are obese – and this figure is projected to continue growing. One potential reason for weight gain and a possible catalyst for obesity is use of pharm…
Read articleAbilify (Aripiprazole) is a medication that was developed by Otsuka Pharmaceuticals and approved by the FDA in 2002 for the treatment of schizophrenia. Approximately 2 years thereafter (in 2…
Read article
